openPR Logo
Press release

Phenylketonuria Treatment Market To Witness A Pronounce Growth By 2026 With Market Dominanats BioMarin Pharmaceutical Inc, Dimension Therapeutics Inc, American Gene Technologies International Inc

10-26-2018 04:53 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Phenylketonuria-Treatment

Phenylketonuria-Treatment

Phenylketonuria (PKU) is a rare genetic disorder caused due to increased level of phenylalanine in the blood. The excess amount of phenylalanine can cause intellectual disability and other serious health problems. The most severe condition of this disorder is termed as classic PKU and symptoms related to it are seizures, tremors, or trembling and shaking, stunted growth, hyperactivity, skin conditions such as eczema, and musty odor of their breath, skin, or urine. PKU can be managed by maintaining phenylalanine free diet. KUVAN (sapropterin dihydrochloride) is a U.S. Food and Drug Administration approved drug which is majorly used in the treatment of Phenylketonuria.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/1648

Phenylketonuria Treatment Market Drivers

Frequent research for development of novel drugs for the treatment of phenylketonuria is expected to drive growth of global phenylketonuria treatment market in the near future. For instance, in 2017, BioMarin Pharmaceutical Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its new Pegvaliase, indicated for the treatment of patients with Phenylketonuria (PKU). In 2018, European Medicines Agency (EMA) accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of adults with phenylketonuria (PKU) who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l). In 2017, Synlogic, Inc. received Orphan Drug Designation for its SYNB1618 from U.S. Food and Drug Administration. SYNB1618, an orally administered synthetic biotic medicine indicated for the treatment of PKU. Furthermore, increasing acquisitions and collaborations between key players is also expected to create a lucrative environment for growth of global phenylketonuria treatment market.

Phenylketonuria Treatment Market Key Players

Key players operating in global phenylketonuria treatment market include BioMarin Pharmaceutical Inc., Dimension Therapeutics, Inc., American Gene Technologies International Inc., Synthetic Biologics, Inc., Codexis, Inc., SOM Innovation Biotech SL, Daiichi Sankyo Company, Limited, and Erytech Pharma SA. Key Players in global phenylketonuria treatment market are focusing on strategic collaborations for the development of novel therapies for the treatment of phenylketonuria. For instance, in January 2018, Retrophin, Inc. and Censa Pharmaceuticals collaborated for the development and evaluation of CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001, is an orally bioavailable proprietary form of sepiapterin, serves as a natural precursor of tetrahydrobiopterin (BH4) that is converted by an endogenous enzymatic pathway to BH4.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/1648

The global Phenylketonuria treatment market is segmented on the basis of treatment type, route of administration, distribution channel, and region:

By Treatment Type-
Drugs
Kuvan
Pegvaliase
Others
Dietary Supplement

By Route of Administration-
Oral
Parenteral

By Distribution Channel-
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region-
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Phenylketonuria Treatment Market To Witness A Pronounce Growth By 2026 With Market Dominanats BioMarin Pharmaceutical Inc, Dimension Therapeutics Inc, American Gene Technologies International Inc here

News-ID: 1332643 • Views: 1914

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Phenylketonuria

Phenylketonuria (PKU) - Pipeline Review, H1 2018
"The Report Phenylketonuria (PKU) - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Phenylketonuria Market Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria (PKU) - Pipeline Review, H1 2018, provides an overview of the Phenylketonuria (PKU) (Metabolic Disorders) pipeline landscape. Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1509364 Phenylketonuria (also called PKU), is a
Phenylketonuria Market To Register Steady Growth During 2025
Phenylketonuria is a genetic disorder, which means it is inherited from one’s parents. In this disease, the patient suffers from a metabolic defect, wherein the body is unable to break down phenylalanine amino acid that is made of protein. Phenylalanine starts accumulating in the blood stream and eventually, it damages the brain. This happens due to mutations in the PAH gene, which result in low levels of the enzyme called
Global Phenylketonuria Market 2017 Forecast to 2022
Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Phenylketonuria Market 2017 Forecast to 2022 TOC and List of Tables & Figures: https://www.researchbymarkets.com/report/global-north-america-europe-and-asia-pacific-south-america-middle-east-and-africa-phenylketonuria-market-2017-forecast-to-2022-2694.html This report studies the phenylketonuria market. Phenylketonuria is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin.
Phenylketonuria (PKU) Market Research Report : 2017
Reports And Markets Publish a New Market Research Report On –"Phenylketonuria (PKU) Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-phenylketonuria-pku-market-research-report-2017-1541147 In this report, the global Phenylketonuria (PKU) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions,
Phenylketonuria (PKU) - Market Insights, Epidemiology, Outlook to 2025
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Phenylketonuria (PKU)-Market Insights, Epidemiology and Market Forecast-2025” to its report offerings. The report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Phenylketonuria (PKU). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265871 The report provides an overview of the disease and in depth research related to Phenylketonuria (PKU) for the 7MM (United States,
Phenylketonuria (PKU) - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylketonuria (PKU) - Pipeline Review, H2 2017”. Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.  Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246570 Report Highlights Global Markets Direct's Pharmaceutical and